Skip to main content


Continuing Education (CME)

2024 SNO/ASCO CNS Metastases Conference
August 8-10, 2024 

This activity is provided by the Society for Neuro-Oncology.

Target Audience
Neuro-oncologists (both neurology and medical oncology-trained), Medical Oncologists, Neurosurgeons, Neuro-radiologists, Neuropathologists, Neuropsychologists, Radiation Oncologists, Basic and Translational Scientists, Data /AI Scientists, Computational scientists, Basic and Clinical Science Trainees, Allied Health Professionals, Palliative Care/Quality of Life Professionals, Industry Professionals, Drug Developers, Regulatory and Government Officials, Patient Advocates, Clinical research specialists, Clinical research organizations -- all involved in clinical trials and patient care of patients with CNS metastases.

Statement of Need/Program Overview
The SNO/ASCO CNS Metastases Conference — Leveraging Multi-Sector Collaboration to Disrupt CNS Metastases — will be held August 8-10, 2024, at the Sheraton Denver Downtown Hotel in Denver, Colorado.

Jointly sponsored by the Society for Neuro-Oncology and the American Society of Clinical Oncology, the scientific content of this unique event will offer outstanding keynote and plenary addresses on a range of timely topics on the complex and rapidly evolving area of CNS metastases. Topics to be addressed include basic and translational research, as well as a broad range of clinical practice topics including radiation therapy, surgery, chemotherapy, targeted therapy/immunotherapy, multimodality therapy and clinical trials. In addition to lectures from internationally recognized experts, conference participants will have opportunities to present their work -- and to learn about advances made by others -- through short oral presentation and scientific posters selected by the scientific review committee. The theme for this year’s conference is to bring together all the key stakeholders and leverage multi-sector collaborations to disrupt barriers and streamline therapeutic advances for patients with CNS metastases.

As an adjunct to the cutting-edge multidisciplinary science that will be presented, we expect the conference in Denver will provide an outstanding and unparalleled forum for networking and socialization with like-minded colleagues from around the world who are focused on advancing CNS metastases research and patient care, as well as the opportunity to interact with exhibitors from SNO’s industry and non-profit partners.

Educational Objectives 
After participating in this CME activity, participants should be able to:
  • Explain the CNS activity of systemic agents in the context of multidisciplinary care for the treatment of CNS metastases.
  • Discuss the evolving role of novel agents with enhanced CNS penetration.
  • Discuss new developments in local therapeutic approaches and diagnostics in the treatment of CNS metastases.
  • Explain the role of the tumor microenvironment in CNS metastases.
  • Discuss innovative clinical trials designs incorporating recent advances such as liquid biopsy, novel prognostic biomarkers, and advanced neuroimaging for the treatment of CNS malignancies
  • Outline challenges for the development and approval of novel therapies for CNS cancers.
Physician Accreditation Statement
The Society for Neuro-Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation
The Society for Neuro-Oncology designates this live activity for a maximum of 9.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit, Claim Certificate of Participation 
In order to receive credit or claim your certificate of participation for this activity, the participant must attend the meeting in-person and complete the program evaluation. An individualized CME/CE evaluation link will be emailed to each participant within one week of the conference conclusion from The Society for Neuro-Oncology with the subject line "Instructions to Claim Credit, Certificate of Participation for the 2024 SNO/ASCO CNS Metastases Conference." 

Deadline to claim CE Credit will be Friday November 1, 2024 at 11:59 pm ET.

Refund/Cancellation Policy 
The deadline for cancellations with refund is Monday, July 29, 2024. Cancellations must be received in writing and a $50 cancellation fee will be assessed. Cancellations received after the deadline date cannot be refunded, but the meeting registration can be transferred to another person with written authorization.

Please note that your SNO membership must be current if you have chosen to register as a SNO member. SNO reserves the right to confirm that you have registered in the correct category.

Payment must be received in full before access to the meeting can be granted.

Email all cancellation and transfer requests to Program Registrar Caroline Noor, [email protected]
Disclosure of Relevant Financial Relationships
The Society for Neuro-Oncology (SNO) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME), stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of accredited continuing education program are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by Society for Neuro-Oncology in accordance with the Standards for Integrity and Independence in Accredited Continuing Education in advance of delivery of the activity to learners. The content of this activity has been vetted to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by SNO. 
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Society for Neuro-Oncology does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
SNO CME Contact Information
For information about the accreditation of this program, please contact the Society for Neuro-Oncology CME Program Manager, MeLesa Ritterhouse, RN at [email protected]

Click here to return to the 2024 SNO/ASCO CNS Metastases Conference homepage.